Evidence map›Paper›PMID 36918365›Full record

ArticleAddiction (Abingdon, England)2023

The impacts of COVID-19 measures on drug markets and drug use among a cohort of people who use methamphetamine in Victoria, Australia.

Kasun Rathnayake, Paul A Agius, Bernadette Ward, Matthew Hickman, Lisa Maher, Mark Stoové, Joseph S Doyle, Margaret Hellard, Anna Wilkinson, Brendan Quinn and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Addiction (Abingdon, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Kasun RathnayakeBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0003-3303-9748
Paul A AgiusBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-6075-8548
Bernadette WardBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-8166-6386
Matthew HickmanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0001-9864-459X
Lisa MaherBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0001-6020-6519
Mark StoovéBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0003-2887-1409
Joseph S DoyleBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0001-7198-0833
Margaret HellardBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-5055-3266
Anna WilkinsonBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-4475-5224
Brendan QuinnBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-2977-3133
Sione CrawfordHarm Reduction Victoria, Melbourne, Victoria, Australia.
Keith SuttonBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-3233-2566
Paul DietzeBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0001-7871-6234
Burnet Institute · AUHarm Reduction Services · USUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsFew studies of the impacts of the coronavirus disease 2019 (COVID-19) public health measures on drug markets and drug use patterns have used longitudinal data. We aimed to examine whether COVID-19 measures were associated with increases in methamphetamine price, decreases in methamphetamine use frequency and subsequent changes in secondary outcomes of other drug use frequency in metropolitan Melbourne and regional Victoria.

designLongitudinal analysis framework was used from a longitudinal cohort of people who use methamphetamine.

settingVictoria state, Australia.

participantsOne hundred eighty-five VMAX study participants who reported a methamphetamine purchase after the onset of the pandemic were used for the price paid analysis. Methamphetamine or other drug use frequency analysis was performed using 277 participants who used methamphetamine during the pandemic or in the year before the pandemic. MEASUREMENTS: Price paid per gram of methamphetamine derived from the most recent purchase price and most recent purchase quantity. Frequency of methamphetamine and other drug use measured as the average number of days per week used in the last month.

findingsCompared with pre-COVID-19 period, methamphetamine prices increased by AUD351.63 (P value <0.001) and by AUD456.51 (P value <0.001) in Melbourne and regional Victoria, respectively, during the period in which the most intense public health measures were implemented in Victoria. Although prices decreased after harder restrictions were lifted (by AUD232.84, P value <0.001 and AUD263.68, P value <0.001, in Melbourne and regional Victoria, respectively), they remained higher than pre-COVID-19 levels. A complementary 76% decrease was observed in relation to methamphetamine use frequency in regional Victoria (P value = 0.006) that was not offset by any changes in the frequency of use of other drugs such as alcohol, tobacco or other illicit drugs.

conclusionCOVID-19 public health measures in Victoria state, Australia, appear to have been associated with major price changes in the methamphetamine market and decreased frequency of use of the drug.

Indexed as

Amphetamine-Related DisordersCOVID-19Illicit DrugsMethamphetamineHumansVictoriaIllicit DrugsMethamphetamineAustraliaCOVID-19dataillicit drugslongitudinalmethamphetaminepeople who use drugspublic health measures

Identifiers

PMID36918365
PMCPMC10953406
OpenAlexW4324304704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.